9 04, 2021

TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

2021-04-09T09:00:05+02:00April 9th, 2021|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, diabetes, microRNAs, microstructure, osteoporosis, Personalized medicine, type 2 diabetes mellitus|Comments Off on TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

TAmiRNA is a key partner in the EU-funded Innovative Training Network FIDELIO, which aims to train the next generation of scientists in tackling the challenges of bone fragility in diabetic patients. The  webinar "MicroRNAs: small RNAs with big potential as biomarkers and drug targets in bone diseases" is a one-hour session hosted by TAmiRNA founder and CEO Dr. Matthias Hackl. He show how microRNAs control gene expression in virtually all human cells and that miRNA expression changes during the onset and progression of (bone) disorders enabling applications as biomarkers and drug targets. He introduce the biological and methodical basics of microRNA research and discuss diagnostic and therapeutic applications of microRNAs in bone disease. [...]

19 01, 2021

Circulating miRNAs in bone health and disease

2021-01-19T10:00:05+01:00January 19th, 2021|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, microstructure, osteoporosis, Personalized medicine|Comments Off on Circulating miRNAs in bone health and disease

We want to draw your attention to our latest review which appeared in the special issue on miRNAs in Bone Research in Bone. In this review, we summarize important molecular basics of microRNA function and release and provide recommendations for best (pre-)analytical practices and documentation standards for circulating microRNA research required for generating high quality data and ensuring reproducibility of results. We review how the genesis of bone-derived circulating microRNAs via release from osteoblasts and osteoclasts could contribute to the communication between these cells and summarize evidence from clinical research studies that have investigated the clinical utility of microRNAs as biomarkers in musculoskeletal disorders. While previous reviews have mainly focused on diagnosis of primary osteoporosis, we have [...]

24 11, 2020

microRNA-146a controls age-related bone loss

2020-11-24T09:00:05+01:00November 24th, 2020|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, microstructure, osteoporosis, Personalized medicine|Comments Off on microRNA-146a controls age-related bone loss

We want to draw your attention to the latest publication in cooperation with TAmiRNA. The study identifies a novel and unexpected role of miR‐146a in bone homeostasis. miR‐146a increases with age and acts as an epigenetic molecular switch terminating bone accrual, leading to bone loss during aging by downregulating bone anabolic Wnt signaling. Conversely, loss of miR‐146a leads to continuous bone accrual during aging as a result of unrestricted bone anabolism and intact Wnt signaling. Therefore, miR‐146a crucially controls the temporal facet of bone homeostasis. "microRNA-146a controls age-related bone loss" Saferding V, Hofmann M, Brunner JS, et al. Aging Cell. 2020 Nov;19(11):e13244. doi: 10.1111/acel.13244. click here to read the story

6 10, 2020

MedUni Wien “Researcher of the Month” Oktober 2020

2020-10-06T12:12:32+02:00October 6th, 2020|biomarker, Liver disease, microRNAs, Personalized medicine|Comments Off on MedUni Wien “Researcher of the Month” Oktober 2020

We want to congratulate Dr. Patrick Starlinger to his award “Researcher of the Month” for his work in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Click here for more information on TAmiRNA services Click here to read the story

1 10, 2020

Dr. Michael Nodine´s Spike-in technology is nominated for a Houska prize

2020-10-01T12:43:31+02:00October 1st, 2020|biomarker, microRNA, microRNA services, Personalized medicine, safety, test service|Comments Off on Dr. Michael Nodine´s Spike-in technology is nominated for a Houska prize

The “Houska“ Prize, awarded annually by the B&C Foundation, is Austria´s biggest private award for applied research. Dr. Michael Nodine, Gregor Mendel Institute of Molecular Plant Biology (GMI), was nominated for his work on the development of methods for nucleic acid quantification. A major issue they encountered was the lack of absolute quantification of small RNA levels, making the comparison between tissues difficult. To overcome this problem, Michael and his team, developed a set of synthetic small RNA Spike-Ins that could be added to these tissue samples. This technology allows us to accurately quantify the levels of different small RNAs that could play a role in several human diseases, ranging from cancer to cardiovascular disease. In 2019, GMI [...]

29 05, 2020

microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring

2020-05-29T10:03:50+02:00May 29th, 2020|biomarker, biomarkers, microRNA, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR|Comments Off on microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring

We want to draw your attention to the latest review of TAmiRNA and the King's College London, in Cardiovascular Diabetology. "microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring." Krammer TL, Mayr M & Hackl M. Int. J. Mol. Sci. 2020, 21(10), 3477; doi.org/10.3390/ijms21103477 In this review, we explain the secretion of miRNAs upon platelet activation and discuss the potential use of platelet-related miRNAs as biomarkers for CVD and antiplatelet therapy monitoring, but also highlight remaining gaps in our knowledge and uncertainties regarding clinical utility. click here to read the story

24 05, 2020

TAmiRNAs SARS CoV-2 offers

2020-07-29T10:49:33+02:00May 24th, 2020|Coronavirus, CoV-2, liquid biopsies, Personalized medicine, SARS, test service, viral RNA|Comments Off on TAmiRNAs SARS CoV-2 offers

TAmiRNA now offers a test service for direct detection of SARS-CoV-2 viral RNA in biological samples. Moreover we offer a validated SARS-CoV-2 Antibody Test (Lateral Flow Method). Click here for more Information

24 02, 2020

TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

2020-02-26T10:44:55+01:00February 24th, 2020|biomarker, biomarkers, drug development, drug discovery, liquid biopsies, LMD, microRNAs, Personalized medicine|Comments Off on TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

The sequencing advance allows genome scale analysis of miRNAs and promises a more efficient discovery approach for safety biomarkers, enabling retrospective analysis. Dr. Kseniya Khamina, TAmiRNA research scientist, will deliver a presentation on ‘Next-generation sequencing pipeline for genome-scale analysis of circulating microRNAs as discovery approach for safety biomarkers’ (P338) during the Biomarkers Poster Session on Day Two, CC Exhibit Hall, of the meeting. The poster was co-authored by TAmiRNA and researchers from the Functional Genomics Center Zurich, Eli Lilly and Company and Merck & Co. Take advantage, meet Kseniya and discuss our latest developments and how TAmiRNA's products and services can assist your business or make an appointment NOW!

13 01, 2020

New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response

2020-01-13T09:00:05+01:00January 13th, 2020|biomarker, biomarkers, clopidogrel, diabetes, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR, type 2 diabetes mellitus|Comments Off on New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response

We want to draw your attention to the latest publication of the King's College London, in Cardiovascular Diabetology. The research team provides new evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response in type-2 diabetics with cardiovascular disease. "Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels." Parker WAE, Schulte C, Bawari T, et al. Cardiovasc Diabetol. 2020 Jan 7;19(1):3. doi: 10.1186/s12933-019-0981-3. click here to read the story

1 01, 2020

meet TAmiRNA 2020

2020-07-20T08:45:02+02:00January 1st, 2020|biomarker, biomarkers, microRNAs, Personalized medicine|Comments Off on meet TAmiRNA 2020

2020 TAmiRNA showcases at several conferences - take advantage, meet the TAmiRNA experts and discuss our latest developments and your needs! 2nd Longevity Therapeutics conference, 28-30 January 2020, San Francisco, California, USA SOT 59th Annual Meeting and ToxExpo, 15-19 March 2020, Anaheim, California, USA - cancelled Osteologie 2020, 5-6 September 2020, virtual meeting 47th annual meeting of the European Calcified Tissue Society, 22-24 October 2020, Marseille, France, virtual meeting